Company Profile

HLB Pharmaceutical Co., Ltd. researches and develops peptide drugs in South Korea. The company offers skeletal muscle relaxant, tranquilizers, antihistamines, antihypertensive agents, pain relief, antipruritics, astringents, anti-inflammatories, alimentary system drugs, metabolic drugs, ophthalmic agents, local anesthetics, antiarteriosclerotic agents, expectorants, antipyretics, analgesics, antidiabetic drug, chemotherapeutics, peptic ulcer agents, central nervous system drug, antibiotics, digestives, antacids, dental drugs, multivitamins, parasistic skin disese drugs, dermatlogicals, agents for urogenital organ, amino acid agent, antitussive, mucolytic agents, anthelmintics, antidiarrheals, circulatory system drug, vitamins, skin softeners, anti-hemorrhoid drugs, and agents for liver disease. It is also developing CTT-004 for the treatment of ataxia induced by spinocerebellar degeneration; and offers CMO services. The company was formerly known as Mediforum Pharmaceutical Incorporation and changed its name to HLB Pharmaceutical Co., Ltd in October 2020. HLB Pharmaceutical Co., Ltd. was founded in 1998 and is headquartered in Namyangju-si, South Korea.

Latest News

Ipsen’s Bylvay fails in Phase III biliary atresia study

Clinical Trials Arena • 07/27/2026

Rothschild & Co Redburn Adjusts PT on Honeywell International to $216 From $214, Keeps Neutral Rating

MT Newswires • 07/27/2026

JPMorgan Adjusts PT on Honeywell International to $262 From $250, Maintains Overweight Rating

MT Newswires • 07/27/2026

Jefferies Adjusts Price Target on Teledyne Technologies to $830 From $775, Maintains Buy Rating

MT Newswires • 07/27/2026

Goldman Sachs Adjusts PT on Teledyne Technologies to $877 From $858, Maintains Buy Rating

MT Newswires • 07/27/2026